Move A Few Dollars Into Mannkind - MNKD
Upgraded to a "BUY" this week by ML/Bank of America.
Afrezza has the potential to be the next blockbuster drug in the treatment of diabetes.
Mannkind is expected to have a "big pharma" marketing partnership in place to launch Afrezza.
Currently trading under $2.00.